September 15, 2026

Photodynamic therapy gains FDA approval for superficial BCC

Phase 3 trial data showed greater clinical and histological clearance than with placebo photodynamic therapy.

MDSpire News

September 08, 2026

Triple-positive profile may flag adverse prostate cancer pathology

A combination of PSA density, MRI, and PSMA PET findings identified a small subgroup with adverse pathology, supporting further study of biopsy-sparing pathways.

MDSpire News

August 28, 2026

FDA monthly preview: Key September decisions to watch

Several FDA decisions across multiple specialties are expected this month.

MDSpire News

August 25, 2026

FDA expands gastroesophageal cancer options

Phase 3 findings showed longer median progression-free survival with zanidatamab-containing regimens vs trastuzumab plus chemotherapy.

MDSpire News

August 19, 2026

Intismeran may improve melanoma end points

Overall survival remains under evaluation as INTerpath-001 continues follow-up.

MDSpire News

August 10, 2026

FDA Approves Melanoma BRAF Companion Test

The assay is indicated to identify patients with advanced melanoma who have BRAF V600E or BRAF V600K variants and may benefit from FDA-approved targeted therapies.

MDSpire News

August 07, 2026

Surgical Site May Raise Infection Risk After Firearm Injury

A nationwide cohort linked selected surgical procedures to higher odds of bacterial infection following firearm injury, while infection was not independently associated with mortality among those who survived 1 night of hospitalization.

MDSpire News

August 03, 2026

FDA Approves Pluvicto for Hormone-Sensitive Prostate Cancer

The approval is based on phase 3 PSMAddition results showing reduced risk of disease progression or death with Pluvicto plus standard of care compared with standard of care alone, according to Novartis.

MDSpire News

July 31, 2026

Postsurgical Ensartinib in ALK-Positive NSCLC

Adjuvant ensartinib may represent a new therapeutic strategy in completely resected disease.

MDSpire News

July 20, 2026

Narrow DCIS Margins May Not Always Warrant Reexcision

An ancillary analysis found less than 2-percentage-point differences in 10-year recurrence across margin thresholds, with no statistically significant adjusted association.

MDSpire News